UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ____________________________________________________________________________ FORM 8-K ____________________________________________________________________________ CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 13, 2025 ____________________________________________________________________________ SI-BONE, INC. (Exact name of registrant as spec ...

Fourth Quarter 2024 worldwide revenue of ~$48.8 to $49.0 million representing growth of ~26%Achieved adjusted EBITDA profitability in the fourth quarter SANTA CLARA, Calif., Jan. 13, 2025 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (NASDAQ:SIBN), a medical device company dedicated to solving sacropelvic disorders, today announced its preliminary and unaudited revenue and cash and cash equivalents for fourth quarter and full year 2024. Fourth Quarter 2024 Summary (any comparisons are to the prior year period) Worldwid ...

Shares of Si-Bone (SIBN) have gained 5.3% over the past four weeks to close the last trading session at $13.83, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $22.78 indicates a potential upside of 64.7%.The mean estimate comprises nine short-term price targets with a standard deviation of $5.07. While the lowest estimate of $15 indicates an 8.5% increase from the current price ...

Si-Bone (SIBN) closed the last trading session at $12.65, gaining 3.1% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $23.22 indicates an 83.6% upside potential.The mean estimate comprises nine short-term price targets with a standard deviation of $4.44. While the lowest estimate of $18 indicates a 42.3% increase from the current price level, the most optimistic analyst expects th ...

SANTA CLARA, Calif., Nov. 20, 2024 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving sacropelvic disorders, today announced that the company will be participating in the upcoming Piper Sandler Healthcare Conference in New York. Management will be hosting a fireside chat on Wednesday, December 4, 2024, at 11:00 a.m. Eastern Time / 8:00 a.m. Pacific Time. Investors interested in listening to the conference call may do so by registering at this link: https://event. ...

Si-Bone (SIBN) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a loss of $0.22. This compares to loss of $0.25 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 27.27%. A quarter ago, it was expected that this medical device maker would post a loss of $0.26 per share when it actually produced a loss of $0.22, delivering a surprise of 15.38%.Over the last four quarters, the company has sur ...

SANTA CLARA, Calif., Nov. 12, 2024 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq:SIBN), a medical device company dedicated to solving sacropelvic disorders, today reported financial results for the quarter ended September 30, 2024. Third Quarter 2024 Financial Highlights (any comparisons are to the prior year period) Worldwide revenue of $40.3 million, representing growth of ~19%  U.S. revenue of $38.3 million, representing growth of ~18%Gross margin of ~79%Net loss of $6.6 million, representing an improvement ...

SANTA CLARA, Calif., Nov. 05, 2024 (GLOBE NEWSWIRE) -- SI-BONE, Inc., (Nasdaq: SIBN), a Silicon Valley-based medical device company dedicated to providing surgical solutions for sacropelvic disorders, today announced that the Centers for Medicare & Medicaid Services (CMS) has granted Transitional Pass-Through (TPT) payment status for the iFuse Bedrock Granite™ (Granite) system, used for pelvic fixation and sacroiliac joint fusion in conjunction with lumbar spinal fusion procedures, under the Medicare Hospit ...

Si-Bone (SIBN) shares rallied 6.9% in the last trading session to close at $13.11. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 12.2% loss over the past four weeks. Si-Bone scored a strong price increase, on investors' optimism surrounding its impending third-quarter 2024 financial results, which is slated to release on Nov. 12 post the closing bell. The Zacks Consensus Estimate for the third quarter reven ...

Company Overview - SI-BONE, Inc. is a global leader in technology for the surgical treatment of sacropelvic disorders [2] - The company has supported over 3,900 surgeons in performing more than 100,000 sacropelvic procedures since pioneering minimally invasive surgery of the SI joint in 2009 [2] - SI-BONE has a strong clinical evidence base, including two randomized controlled trials and over 135 peer-reviewed publications [2] Upcoming Financial Results - SI-BONE will report its financial results for the third quarter of 2024 after market close on November 12, 2024 [1] - A conference call will be hosted by management at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time on the same day [1] - Investors can access the live audio of the webcast through the company's website, and it will be archived for at least 90 days [1]